Chlorpheniramine

CHEMBL505 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
274.8 g/mol
LogP
3.4
Phase
4

A first-generation antihistamine of the alkylamine class that blocks H1 receptors to relieve allergic rhinitis, hay fever, urticaria, and cold symptoms. It crosses the blood-brain barrier and commonly causes sedation. It is widely available in over-the-counter preparations, often in combination with decongestants and analgesics.

分子量

274.7900 g/mol

LogP

3.40

TPSA

16.10 Ų

リピンスキーの五則

適合

治療領域

作用機序

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1

InChI

InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3

Molecular Formula

C16H19ClN2

HBD / HBA

- / 2

回転可能結合数

5

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A first-generation antihistamine of the alkylamine class that blocks H1 receptors to relieve allergic rhinitis, hay fever, urticaria, and cold symptoms. It crosses the blood-brain barrier and commonly causes sedation. It is widely available in over-the-counter preparations, often in combination with decongestants and analgesics.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Chlorpheniramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL505. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2725. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.